Syndax Pharmaceuticals (SNDX) EBITDA (2015 - 2026)

Syndax Pharmaceuticals' EBITDA history runs 12 years deep, the most recent figure standing at -$34.2 million for Q1 2026.

• In Q1 2026, EBITDA rose 59.17% year-over-year to -$34.2 million; the TTM figure through Mar 2026 stood at -$223.5 million (up 32.51% YoY), while the FY2025 annual figure was -$273.1 million, up 19.6% from the prior year.
• EBITDA was -$34.2 million for Q1 2026 at Syndax Pharmaceuticals, up from -$62.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$34.2 million in Q1 2026 to a low of -$96.4 million in Q4 2024.
• Historically, EBITDA has averaged -$58.6 million across 5 years, with a median of -$57.4 million in 2025.
• The sharpest annual moves came in 2022 and 2026: EBITDA slumped 143.9% in 2022, then surged 59.17% in 2026.
• A 5-year view of EBITDA shows it stood at -$42.0 million in 2022, then plunged by 85.34% to -$77.9 million in 2023, then dropped by 23.7% to -$96.4 million in 2024, then jumped by 35.09% to -$62.5 million in 2025, then soared by 45.32% to -$34.2 million in 2026.
• The last three EBITDA figures came in at -$34.2 million (Q1 2026), -$62.5 million (Q4 2025), and -$57.4 million (Q3 2025), per Business Quant data.